REFERENCES
1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
3. Lazarus JV, Mark HE, Anstee QM, et al. NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022;19:60-78.
4. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901-10.
5. Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in Adults. Focus on clinical aspects and implications for practice and translational research. J Clin Med 2020;9:1278.
6. Stachenfeld NS, Mazure CM. Precision medicine requires understanding how both sex and gender influence health. Cell 2022;185:1619-22.
7. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022;71:778-88.
8. Yi M, Peng W, Feng X, et al. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment Pharmacol Ther 2022;56:1119-30.
9. Thomas JA, Kendall BJ, Dalais C, Macdonald GA, Thrift AP. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Cancer 2022;173:250-62.
10. Polyzos SA, Kang ES, Tsochatzis EA, et al. Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism 2020;113:154413.
12. Liu Z, Lin C, Suo C, et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism 2022;127:154955.
13. Wei S, Hao Y, Dong X, et al. The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer. Front Endocrinol 2023;14:985858.
14. Yuan X, Wang X, Wu S, et al. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China. Hepatobiliary Surg Nutr 2023;12:671-81.
15. Chung GE, Yu SJ, Yoo JJ, et al. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects. Cancer Commun 2023;43:863-76.
16. Crudele L, De Matteis C, Graziano G, et al. AST/ALT-to-platelet ratio (AARPRI) predicts gynaecological cancers: a 8-years follow-up study in 653 women. Sci Rep 2023;13:17793.
17. Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study. J Hepatol 2019;71:1229-36.
18. Lonardo A, Roncucci L. The "obese liver" and gastrointestinal cancer risk. Transl Gastroenterol Hepatol 2020;5:44.
19. Lonardo A, Suzuki A. Concise review: breastfeeding, lactation, and NAFLD. An updated view of cross-generational disease transmission and prevention. Metab Target Organ Damage 2023;3:16.
20. Lin X, Chen C, Jiang T, et al. Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with cervical stromal involvement in endometrial cancer patients: a cross-sectional study in South China. Curr Oncol 2023;30:3787-99.
21. Tai J, Hsu CW, Chen WT, et al. Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype. Cancer Sci 2024;115:564-74.
22. Dolce A, Della Torre S. Sex, nutrition, and NAFLD: relevance of environmental pollution. Nutrients 2023;15:2335.
23. Yang L, Tu PH, Zhang CX, et al. Influence of two anti-tumor drugs, pazopanib, and axitinib, on the development and thyroid-axis of zebrafish (Danio rerio) embryos/larvae. Front Endocrinol 2023;14:1204678.
24. Wahlang B, Jin J, Beier JI, et al. Mechanisms of environmental contributions to fatty liver disease. Curr Environ Health Rep 2019;6:80-94.
25. Sen P, Qadri S, Luukkonen PK, et al. Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. J Hepatol 2022;76:283-93.
26. Rives C, Fougerat A, Ellero-Simatos S, et al. Oxidative stress in NAFLD: role of nutrients and food contaminants. Biomolecules 2020;10:1702.
27. Liu W, Li M, Guo H, et al. Single-cell transcriptome analysis of liver immune microenvironment changes induced by microplastics in mice with non-alcoholic fatty liver. Sci Total Environ 2024;912:168308.
28. Ye Z, Liu M, He P, et al. Various ambient air pollutants, residential green spaces, fibrosis 4 scores, genetic susceptibility, and risk of severe liver disease. Ecotoxicol Environ Saf 2023;263:115246.
29. Tovoli F, Stefanini B, Mandrioli D, et al. Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: a prospective pilot study. Dig Liver Dis 2023;Online ahead of print:S1590-8658(23)01097-6.
30. Wen Q, Liu T, Yu Y, et al. Self-reported primary cooking fuels use and risk of chronic digestive diseases: a prospective cohort study of 0.5 million Chinese adults. Environ Health Perspect 2023;131:47002.
31. Cazzolla Gatti R, Di Paola A, Monaco A, Velichevskaya A, Amoroso N, Bellotti R. The spatial association between environmental pollution and long-term cancer mortality in Italy. Sci Total Environ 2023;855:158439.
32. Eom SY, Choi J, Bae S, et al. Health effects of environmental pollution in population living near industrial complex areas in Korea. Environ Health Toxicol 2018;33:e2018004.
33. Korsh J, Shen A, Aliano K, Davenport T. Polycyclic aromatic hydrocarbons and breast cancer: a review of the literature. Breast Care 2015;10:316-8.
34. Park JH, Hong S, Kim OH, et al. Polypropylene microplastics promote metastatic features in human breast cancer. Sci Rep 2023;13:6252.
35. Sulaiman SA, Dorairaj V, Adrus MNH. Genetic polymorphisms and diversity in nonalcoholic fatty liver disease (NAFLD): a mini review. Biomedicines 2022;11:106.
36. George ES, Sood S, Kiss N, et al. The evidence surrounding non-alcoholic fatty liver disease in individuals with cancer: a systematic literature review. Curr Oncol 2022;30:48-74.
